Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19

Chia Siang Kow, Syed Tabish Razi Zaidi, Syed Shahzad Hasan

Research output: Contribution to journalReview article


There is ongoing debate on the safety of renin-angiotensin system (RAS) inhibitors in COVID-19. Recently published studies highlight a potential relationship between cardiovascular disease (CVD) and COVID-19. This article aims to summarize the evidence on the use of RAS inhibitors in CVD patients with COVID-19, focusing on safety issues of the RAS inhibitors and their relationship with COVID-19.
Original languageEnglish
Number of pages5
JournalAmerican Journal of Cardiovascular Drugs
Early online date13 Apr 2020
Publication statusE-pub ahead of print - 13 Apr 2020


Cite this